Asuka Pharmaceutical plans to submit a proposal to seek shareholder approval for the implementation of countermeasures against large-scale purchase attempts by Dalton and others at the upcoming general meeting. The company will continue to prioritize protecting medium- and long-term corporate value against future acquisition activities.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4886","jir_company_name":"Asuka Pharmaceutical Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-25","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4886-20260525-04.pdf","jir_short_summary":"Asuka Pharmaceutical plans to submit a proposal to seek shareholder approval for the implementation of countermeasures against large-scale purchase attempts by Dalton and others at the upcoming general meeting. The company will continue to prioritize protecting medium- and long-term corporate value against future acquisition activities.","jir_summary":"### Implementation of Countermeasures for the Shareholders' Meeting\nAsuka Pharmaceutical is scheduled to hold a shareholders' meeting on June 24, 2026, where it plans to submit a proposal to authorize the implementation of countermeasures in anticipation of purchase attempts by Dalton and others. This framework allows the company to activate countermeasures without shareholder approval if the purchase activities do not adhere to the established procedural guidelines. The Board of Directors respects the recommendations of the Independent Committee and is preparing responses to maximize corporate value and shareholder interests.\n\n### Future Outlook and Impact on Shareholders\nAs the likelihood of Dalton and others executing large-scale purchase attempts increases, Asuka Pharmaceutical intends to seek shareholder approval at the upcoming general meeting to activate countermeasures aimed at preventing damage to long-term corporate value. If purchase activities occur, the company will protect minority shareholders\u2019 interests and ensure management stability while addressing conflicts of interest and hostile takeover risks. These actions aim to safeguard shareholder interests and promote sustainable corporate growth.","jir_financial_highlights":"","jir_category":"","jir_hashtags":"#AsukaPharmaceutical, #IRRelated, #JapaneseStocks","jir_key_figures":"Proposal submission date at shareholders' meeting: June 24, 2026\nStatus of purchase attempt: Intended (contingency)\nConditions for implementing countermeasures: If large-scale purchase attempts are executed without following the procedures in this policy","jir_meta_title":"\u3010Asuka Pharmaceutical\u3011 Approves Shareholders\u2019 Meeting Countermeasures Against Large-Scale Purchases \uff5c May 2026","jir_meta_description":"Asuka Pharmaceutical plans to seek approval for the implementation of countermeasures at the shareholders' meeting in anticipation of large-scale purchase attempts by Dalton and others. The company is progressing with strategies to protect corporate value and shareholder interests.","jir_og_title":"\u3010Asuka Pharmaceutical\u3011 Shareholders\u2019 Meeting to Approve Purchase Countermeasures \uff5c May 2026","jir_og_description":"Asuka Pharmaceutical is planning to seek approval at the shareholders' meeting for countermeasures against purchase attempts by Dalton and others. The company aims to safeguard corporate value and shareholder interests.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17164,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-54416","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n